Clinical Trial Update: Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating intravitreal Ozurdex after pars plana vitrectomy for proliferative diabetic retinopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: Anders Kvanta | Conditions: Proliferative Diabetic Retinopathy | Phase 2 | Status: COMPLETED